Elanco Animal Health (ELAN) Non-Current Assets (2017 - 2026)
Elanco Animal Health (ELAN) posted Non-Current Assets of $9.6 billion for Q1 2026, down 2.65% sequentially from $9.9 billion in Q4 2025, and up 1.44% YoY from $9.5 billion in Q1 2025.
Elanco Animal Health (ELAN) Non-Current Assets (2017 - 2026) Analysis & Trends
Elanco Animal Health has reported Non-Current Assets for 10 years, with the latest figure at $9.6 billion in Q1 2026.
- Quarterly Non-Current Assets rose 1.44% year-over-year to $9.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.7 billion (up 2.99% YoY) and the FY2025 annual result came in at $9.9 billion, up 5.33% from the prior year.
- Non-Current Assets declined to $9.6 billion in Q1 2026 per ELAN's latest filing, from $9.9 billion in the prior quarter.
- Over five years, Non-Current Assets peaked at $13.1 billion in Q1 2022 and troughed at $9.4 billion in Q4 2024.
- A 5-year average of $10.8 billion and a median of $10.1 billion in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets slipped 19.69% in 2024, then increased 5.33% in 2025.
- Over 5 years, Non-Current Assets stood at $12.2 billion in 2022, then declined by 10.29% to $11.0 billion in 2023, then retreated by 14.2% to $9.4 billion in 2024, then gained by 5.33% to $9.9 billion in 2025, then fell by 2.65% to $9.6 billion in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $9.6 billion, $9.9 billion, and $10.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.76 Bn |
| Mar 31, 2026 | 9.64 Bn |
| Dec 31, 2025 | 9.90 Bn |
| Sep 30, 2025 | 10.06 Bn |
| Jun 30, 2025 | 10.13 Bn |
| Mar 31, 2025 | 9.50 Bn |
| Dec 31, 2024 | 9.40 Bn |
| Sep 30, 2024 | 9.92 Bn |
| Jun 30, 2024 | 9.75 Bn |
| Mar 31, 2024 | 9.97 Bn |
| Dec 31, 2023 | 10.96 Bn |
| Sep 30, 2023 | 10.78 Bn |
| Jun 30, 2023 | 12.14 Bn |
| Mar 31, 2023 | 12.22 Bn |
| Dec 31, 2022 | 12.21 Bn |
| Sep 30, 2022 | 11.79 Bn |
| Jun 30, 2022 | 12.29 Bn |
| Mar 31, 2022 | 13.06 Bn |
| Dec 31, 2021 | 13.20 Bn |
| Sep 30, 2021 | 13.41 Bn |